ArticleBMC microbiology2025
Phage vB_KpnM_JYSS3 encodes a novel polysaccharide depolymerase that exhibits specific activity against K2-type carbapenem-resistant Klebsiella pneumoniae.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Therapeutic efficacy of a K1-specific bacteriophage against hypervirulent Klebsiella pneumoniae in a mouse infection model.Virologica Sinica · 2026Article
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Phage and endolysin-based inhibition ofFrontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundCarbapenem-resistant Klebsiella pneumoniae (CRKP), a major nosocomial pathogen, poses an increasingly serious threat to human health.
resultsIn the quest for innovative therapeutic modalities to treat CRKP infections, a newly discovered phage, vB_KpnM_JYSS3, which can specifically infect and lyse K2-type CRKP, was isolated and subjected to an array of comprehensive characterizations and genome sequencing. Furthermore, an analysis of the expression of the tail protein (ORF17) and the detection of its functions were carried out. Double-layer agar plates containing CRKP were used to isolate phages from hospital sewage samples. The phage's optimal multiplicity of infection (MOI), lytic spectrum, bactericidal activity, stability, and one-step growth curve were tested. The biofilm development ability of the CRKP strain 21AA2216 and the phage antibiofilm activity were determined using a 96-well microtitration plate. vB_KpnM_JYSS3 prevented biofilm generation and broke down mature biofilms. The whole-genome sequencing results revealed that vB_KpnM_JYSS3 is a toxic phage (nontemperate). The genome size of vB_KpnM_JYSS3 is 47,244 bp, and the G + C content is 48.48 mol%. A total of 71 coding sequences (CDSs) were predicted. Protein function prediction revealed that the tail protein (ORF17) of vB_KpnM_JYSS3 may possess depolymerase activity, consistent with the halo phenomenon around the plaque. ORF17 was expressed, purified, and named Dep17. Dep17 can degrade the capsular polysaccharide (CPS) surrounding K2-type CRKP, and it can also enhance the activity of polymyxin B against K2-type CRKP biofilms.
conclusionsPhage vB_KpnM_JYSS3 and its novel depolymerase Dep17 may represent promising strategies for combating infections resulting from biofilm-forming and drug-resistant K2-type CRKP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.